Healthcare company Viatris (VTRS) grabbed investors’ attention when its first interchangeable biosimilar drug received FDA approval recently. However, given that it could...
By Nate Raymond (Reuters) - Pfizer Inc (NYSE:PFE) has agreed to pay $345 million to resolve claims by consumers who say they overpaid for EpiPens due to anticompetitive...
Viatris (VTRS) is a pharmaceutical company that sells a variety of different drugs. The company plans to offer its first ever dividend and is currently trading at a very low...
Investors will focus on pipeline updates when Israel-based clinical-stage immunotherapy company, Enlivex Therapeutics (NASDAQ:ENLV), Ltd ENLV, reports results for the three months...
Adding dividend-paying stocks in a strong industry is one of the best ways to boost your overall returns over the years. Since healthcare is one of the most important issues...
Model N (NYSE:MODN), Inc MODN recently reported preliminary fourth-quarter fiscal 2020 results, wherein the management stated that the company’s revenue and profitability...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,702.50 | 2,713.00 | 2,689.70 | -10.1 | -0.37% | 983.80K | NASDAQ | |||
| 358.92 | 360.48 | 351.51 | +7.68 | +2.19% | 14.18M | NASDAQ | |||
| 146.94 | 148.67 | 134.92 | +8.15 | +5.87% | 1.55M | NASDAQ | |||
| 200.71 | 203.27 | 196.91 | +3.33 | +1.69% | 22.33M | NYSE | |||
| 70.39 | 85.00 | 54.40 | +23.59 | +50.41% | 175.79M | NASDAQ | |||
| 163.82 | 167.42 | 163.58 | -0.27 | -0.16% | 3.29M | NASDAQ | |||
| 29.84 | 35.24 | 29.81 | -3.75 | -11.16% | 85.50M | NYSE | |||
| 202.74 | 203.18 | 198.28 | +4.59 | +2.32% | 23.13M | NASDAQ | |||
| 30.60 | 31.18 | 30.33 | -0.11 | -0.36% | 5.13M | NYSE | |||
| 126.66 | 127.78 | 125.92 | -1.27 | -0.99% | 954.45K | NYSE | |||
| 231.07 | 235.39 | 230.94 | -1.98 | -0.85% | 1.15M | NYSE | |||
| 148.22 | 149.20 | 147.33 | +0.27 | +0.18% | 5.56M | NASDAQ | |||
| 98.63 | 106.80 | 98.58 | -8.15 | -7.63% | 1.73M | NYSE | |||
| 202.10 | 205.89 | 191.68 | +11.64 | +6.11% | 6.19M | NASDAQ | |||
| 48.20 | 49.14 | 47.87 | -0.29 | -0.60% | 101.26K | NASDAQ |
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.